Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy

Enzymes

Volumn 32, Issue , 2012, Pages 185-203

  Yanes, Rolando E ^a   Lu, Jie ^a   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Delivery; Nanoparticles; Signal transduction

Indexed keywords

EID: 84869220339     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-404741-9.00009-X     Document Type: Chapter

References (63)

1. Deepak N., Zack T.I., Ren Y., Strickland M.R., Lamothe R., Schumacher S.E., et al. Cancer vulnerabilities unveiled by genomic loss. Cell 2012, 150:842-854.
2. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. The Cancer Genome Atlas Research Network.
3. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., Wang H., et al. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics 2005, 5:173-190.
4. Seyhan A.A. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 2011, 130:583-605.
5. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systematically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
6. Fabian M.R., Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012, 19:586-593.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Chen J., Wall N.R., Kocher K., Duclos N., Fabbro D., Neuberg C., et al. Stable expression of small interfering RNA sintesizes TEL-PDGFβR to inhibition with imatinib or rapamycin. J Clin Invest 2004, 113:1784-1791.
9. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
10. Scherr M., Battmer K., Winkler T., Heindenreich O., Ganser A., Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003, 101:1566-1569.
11. Wohbold L., Van Der Kuip H., Meithing C., Vornlocher H.-P., Knabbe C., Duyster J., et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mysylate (STI571). Blood 2003, 102:2236-2239.
12. Koldehoff M., Steckel N.K., Beelen D.W., Elmaagacli A.H. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukemia. Clin Exp Med 2007, 7:47-55.
13. Sumimoto H., Hirata K., Yamagata S., Miyoshi H., Miyagishi M., Taira K., et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006, 118:472-476.
14. Kock N., Kasmieh R., Weissleder R., Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 ans S-TRAIL. Neoplasia 2007, 9:435-442.
15. Ge L., Shao W., Zhang Y., Qiu Y., Cui D., Huang D., et al. RNAi targeting of hTERT gene expression induces apoptosis and inhibits the proliferation of lung cancer cells. Oncol Lett 2011, 2:1121-1129.
16. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
17. Zhu H., Liang Z.Y., Ren X.Y., Liu T.H. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther 2006, 5:1693-1698.
18. Liu X., Liu L., Xu Q., Wu P., Zuo X., Ji A. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther 2012, 12:573-580.
19. Link A., Becker V., Goel A., Wex T., Malfertheiner P. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One 2012, 7:e42933.
20. Dong P., Kaneuchi M., Watari H., Hamada J., Sudo S., Ju J., et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011, 10:99.
21. Gao P., Xing A.-Y., Zhou G.-Y., Zhang T.-G., Zhang J.-P., Gao C., et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 2012, 10.1038/onc.2012.61.
22. Zhao X., Dou W., He L., Liang S., Tie J., Liu C., et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 2012, 1-10. 10.1038/onc.2012.156.
23. Wu Z.-S., Wang C.-Q., Xiang R., Liu X., Ye S., Yang X.-Q., et al. Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 2012, 12:51.
24. Li Y., VandenBoom T.G., Wang Z., Kong D., Ali S., Philip P.A., et al. miRNA-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010, 70:1486-1495.
25. Hamada S., Satoh K., Fujibuchi W., Hirota M., Kanno A., Unno J., et al. MiR-126 acts as a tumor suppressor in pancreatic cáncer cells via the regulation of ADAM9. Mol Cancer Res 2011, 10:3-10.
26. Soubani O., Ali A.S., Logna F., Ali S., Philip P.A., Sarkar F.H. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 2012, 33:1563-1571.
27. Hom C., Lu J., Tamanoi F. Silica nanoparticles as a delivery system for nucleic acid-based reagents. J Mater Chem 2009, 19:6308-6316.
28. Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24:1504-1534.
29. Park I.Y., Kim I.Y., Yoo M.K., Choi Y.J., Cho M.H., Cho C.S. Mannosylated polyethylenimine coupled mesoporous silica nanoparticles for receptor-mediated gene delivery. Int J Pharm 2008, 359:280-287.
30. Yanes R.E., Tamanoi F. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Ther Deliv 2012, 3:389-404.
31. Miller S.A., Hong E.D., Wright D. Rapid and efficient enzyme encapsulation in a dendrimer silica nanocomposite. Macromol Biosci 2006, 6:839-845.
32. Radu D.R., Lai C.Y., Jeftinija K., Rowe E.W., Jeftinija S., Lin V.S. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection agent. J Am Chem Soc 2004, 126:13216-13217.
33. Lu J., Li Z., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8:212-220.
34. Lu J., Liong M., Li Z., Zink J.I., Tamanoi F. Biocompatability, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010, 6:1794-1805.
35. Hom C., Lu J., Liong M., Luo H., Li Z., Zink J.I., et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 2010, 6:1185-1190.
36. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
37. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
38. Li X., Xie Q.R., Zhang J., Xia W., Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 2011, 32:9546-9556.
39. Chen Y., Chu C., Zhou Y., Ru Y., Chen H., Chen F., et al. Reversible pore-structure evolution in hollow silica nanocapsules: large pores for siRNA delivery and nanoparticle collecting. Small 2011, 7:2935-2944.
40. Na H.K., Kim M.H., Park K., Ryoo S.R., Lee K.E., Jeon H., et al. Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 2012, 8:1752-1761.
41. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011, 19:900-914.
42. Ashley C.E., Carnes E.C., Epler K.E., Padilla D.P., Phillips G.K., Castillo R.E., et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 2012, 6:2174-2188.
43. Jeffs L.B., Palmer L.R., Ambegia E.G., Giesbrecht C., Ewanick S., MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005, 22:362-372.
44. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNA's. Nat Biotechnol 2005, 23:1001-1007.
45. Mounkes L.C., Zhong W., Cipres-Palacin G., Heath T.D., Debs R.J. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 1998, 273:26164-26170.
46. Cullis P.R., Krujiff B. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim Biophys Acta 1979, 559:399-420.
47. Liu Y., Liggitt D., Zhong W., Tu G., Gaensler K., Debs R. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995, 270:24864-24870.
48. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
49. Briane D., Slimani H., Tagounits A., Naejus R., Haddad O., Coudert R., et al. Inhibition of VEGF expression in A431 and MDA-MB 231 tumor cells by cationic lipid-mediated siRNA delivery. J Drug Target 2012, 20:347-354.
50. Gomes-da-Silva L.C., Santos A.O., Bimbo L.M., Moura V., Ramalho J.S., Pedroso de Lima M.C., et al. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharm 2012, 434:9-19.
51. Mokhtarieh A.A., Cheong S., Kim S., Chung B.H., Lee M.K. Asymmetric liposome particles with highly efficient encapsulation of siRNA and without nonspecific cell penetration suitable for target-specific delivery. Biochim Biophys Acta 2012, 1818:1633-1641.
52. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking on non-viral gene delivery particles. Eur J Cell Biol 2004, 83:97-111.
53. Sato A., Choi S.W., Hirai M., Yamayoshi A., Moriyama R., Yamano T., et al. Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life. J Control Release 2007, 122:209-216.
54. Glodde M., Sirsi S.R., Lutz G.J. Physiochemical properties of low and high molecular weight poly(ethylene glycol)-Grafted Poly(ethylene imine) copolymers and their complexes with oligonucleotides. Biomacromolecules 2006, 7:347-356.
55. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 1999, 10:1068-1074.
56. Bartlett D.W., Davis M.E. Physicochemical and biological characterization of targeted, nucleic acid containing nanoparticles. Bioconjug Chem 2007, 18:456-468.
57. Alabi C., Vegas A., Anderson D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol 2012, 12:427-433.
58. Kukarni R.P., Mishra S., Fraser S.E., Davis M.E. Single cell kinetics of intracellular, nonviral, nucleic acid delivery vehicle acidification and trafficking. Bioconjug Chem 2005, 16:986-994.
59. Barlett D.W., Davis M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 2008, 99:975-985.
60. Klein S., Zolk O., Fromm M.F., Schrodl S., Neuhuber W., Kryschi C. Functionalized silicon quantum dots tailored for targeted siRNA delivery. Biochem Biophys Res Commun 2009, 387:164-168.
61. Li J.-M., Zhao M.-X., Su H., Wang Y.-Y., Tan C.-P., Ji L.-N. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracelular imaging. Biomaterials 2011, 32:7978-7987.
62. Li J.-M., Wang Y.-Y., Zhao M.-X., Tan C.-P., Li Y.-Q., Le X.-Y., et al. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 2012, 33:2780-2790.
63. Lin Q., Chen J., Jin H., Ng K.K., Yang M., Cao W., et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine (Lond) 2012, 10.2217/nnm.12.73.